Generic drugmaker Granules India reported September quarter consolidated net profit increased nearly 34% to ₹130 crore compared to ₹97.2 crore a year earlier.
The higher net profit came a more than 34% increase in total revenue from operations at almost ₹1,297 crore (₹966.6 crore).
It was a resilient financial performance with healthy growth in both revenue and profitability. The improvement in PAT reflects the continued focus on operational excellence, disciplined execution and the strength of governance, CMD Krishna Prasad Chigurupati said.
Finished dosages (FD), active pharmaceuticals ingredients (APIs), pharmaceutical formulation intermediates (PFI), and peptides/ CDMO contributed 74%, 13%, 10% and 2% to revenue from operations respectively during the quarter.
“Our peptides CDMO platform through Ascelis, anchored in the legacy of Senn Chemicals in Switzerland, is steadily gaining visibility, with renewed customer interest and promising new discussions underway,” he said in a release. Granules shares closed 2.52% higher on Thursday at ₹555.85 apiece on the BSE.
The company said among other things, the Board has approved acquisition of 100% stake in a new company, optus 1039 GmBH, in Frankfurt for euro 28,400 (nearly ₹29.10 lakh) as part of plans to establish a wholly owned subsidiary in Germany for the pharmaceutical business. The move will enable Granules’ entry into the B2C segment in the European region. The acquisition is aimed at strengthening consumer engagement and driving focused growth across key European markets, it said.
Published – November 13, 2025 10:23 pm IST
